Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs

HALO develops novel oncology treatments targeting tumors and offers a health care technology platform for subcutaneous drug delivery that is used by other pharmaceutical companies as well. Its first-quarter fiscal 2026 earnings report showed record revenue of $377 million (a 42% year-over-year rise), non-GAAP diluted per-share earnings of $1.60 (a 44.1% gain), and raised 2026 revenue and EPS guidance to high ends of $1.81 billion and $8.25, respectively. The company reports again on Aug. 11.

It’s no wonder HALO shares are up 52% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Halozyme Gets Big Money Buys

Institutional volumes reveal plenty. In the last year, HALO has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in HALO shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Halozyme.

Halozyme Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, HALO has had strong sales and earnings growth:

• 3-year sales growth rate (+28.5%)
• 3-year EPS growth rate (+28%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +24.3%.

Now it makes sense why the stock has been generating Big Money interest. HALO has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Halozyme has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s drawn 26 outlier inflow signals since 2014 and is up 539% since Big Money first bought big. The blue bars below show when HALO was a top pick on the Outlier 20 report in the last five years…institutional support lifts shares over time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Halozyme Price Prediction

The HALO action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in HALO at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.